What did @realdrbae actually say?
The creator, who introduces himself as a "board sort of" plastic surgeon, argues that GI side effects like nausea, vomiting, constipation, and bloating are essentially inevitable on semaglutide, while gastroparesis is "extraordinarily rare." He also tells viewers to ask their provider for Zofran to manage nausea.
To be fair, the core message here is reasonable: common GI symptoms are well-documented with GLP-1 medications, and fear-driven TikTok content about "stomach paralysis" does tend to overstate that risk. He also correctly frames delayed gastric emptying as a mechanism of action, not just a side effect. That framing matters.
Where it gets shaky is the blanket "you will get these side effects" framing. That is an overstatement. Rates vary significantly by dose, titration speed, and individual tolerance. Not everyone on semaglutide vomits. Some people tolerate it without any notable GI complaints.
Does the science back this up?
Mostly, yes, with some important caveats. The clinical trial data does show GI adverse events are the most common reason people discontinue GLP-1 therapy, but "most common" does not mean universal.
In the SUSTAIN and STEP trial programs, nausea occurred in roughly 20 percent of semaglutide users versus around 6 percent on placebo (Davies et al., 2021, Diabetes Care). Vomiting and diarrhea followed similar patterns. These numbers are meaningful, but they also mean the majority of participants did not report these symptoms at a level worth flagging.
On gastroparesis specifically, the creator is on solid ground. A 2023 JAMA Internal Medicine study (Sodhi et al.) found an increased risk of gastroparesis diagnosis in GLP-1 users compared to bupropion-naltrexone users, with an adjusted hazard ratio around 3.67. That sounds alarming, but the absolute incidence remained low. The creator calling it "extraordinarily rare" is defensible.
What did they get wrong (or right)?
Right: Delayed gastric emptying is genuinely part of how these medications work, and distinguishing that from clinical gastroparesis is a useful clarification most TikTok creators skip entirely. Credit where it is due.
Right: The side effects he lists are the ones actually documented in trials. No invented symptoms, no exaggeration of severity.
Wrong: "You will get these side effects" is too strong. A more accurate claim is that a significant minority of patients experience them, with risk increasing at higher doses and faster titration schedules. Blanket certainty here could either discourage people who would tolerate the medication fine, or prime them to expect symptoms they might not otherwise notice.
Questionable: Recommending Zofran (ondansetron) by name to a general audience of millions is a real overstep. Ondansetron has a QT-prolongation risk profile that warrants individual clinical assessment, not a mass suggestion. That recommendation should have stayed in a clinical conversation, not a TikTok caption.
What should you actually know?
GI side effects with semaglutide are common but not inevitable, and their severity is often tied to how fast the dose is increased. Slower titration is consistently associated with better tolerability. If a provider is rushing your dose escalation, that is worth pushing back on.
The gastroparesis story is genuinely complicated. The Sodhi et al. (2023) study raised legitimate signals that the medical community is still working through. Calling it "extraordinarily rare" is accurate for now, but surveillance is ongoing and the full picture may shift, particularly for patients with pre-existing diabetes-related autonomic dysfunction.
On the Zofran point: ondansetron can help with GLP-1 nausea, and some providers do prescribe it. But it is not a first-line recommendation for everyone, and it is not something to request based on a TikTok video. Talk to a provider who knows your cardiac and medication history before adding it.
- Side effects tend to peak in the first few weeks of a new dose and typically improve with time, as the creator correctly notes.
- Staying hydrated and eating smaller, lower-fat meals can reduce GI burden during titration.
- If symptoms are severe or persistent, dose reduction, not pushing through, is the appropriate clinical response.